Neutralizing activity to SARS-CoV-2 in 1.2 to 10.0 month convalescent plasma samples of COVID-19: A transversal surrogate in vitro study performed in Quito-EcuadorCOVID-19의 1.2~10.0개월 회복기 혈장 샘플에서 SARS-CoV-2에 대한 중화 활성: 키토-에콰도르에서 수행된 횡단 대리 시험관내 연구Article Published on 2022-09-012022-09-11 Journal: Journal of medical virology [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, [키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition analyzed binding domain BSL2 facility BSL3 caused convalescence Convalescent patients convalescent plasma convalescent sera coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 determine diagnostic methods Ecuador glycoprotein IgG IgM Immunoglobulin Immunoglobulin G immunoglobulin M in some in vitro study Infection NAb NAbs neutralization test Neutralizing Neutralizing activity Neutralizing antibodies neutralizing antibody performed plasma positive presence or absence Quito remained reported respiratory SARS-CoV-2 Seroconversion severe acute respiratory syndrome Coronavirus surrogate Test the SARS-CoV-2 Viral viral spike virus Wuhan Wuhan, China [DOI] 10.1002/jmv.27866 PMC 바로가기 [Article Type] Article
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronavirusesOmicron SARS-CoV-2 및 사전 출현 코로나바이러스에 대한 친화성 성숙 ACE2 유인물의 높은 활성Article Published on 2022-08-252022-09-11 Journal: PLoS ONE [Category] SARS, 변종, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adeno-associated virus affinity airway angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antigenic antigenic drift binding can not clade complicate coronavirus coronavirus disease Coronavirus disease 2019 Coronaviruses COVID-19 COVID-19 pandemic decoy develop drug Efficacy Evolution exceptional genetic diversity human ACE2 inhibitor intranasal intrinsic mitigate monoclonal antibody mutant nanomolar affinity Neutralizing omicron pandemic populations preparation Prophylaxis receptor Receptor-binding domain sarbecovirus Sarbecoviruses SARS-CoV-1 SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants severe acute respiratory syndrome Coronavirus Spike protein the SARS-CoV-2 the spike protein therapeutic Threats Treatment Vaccine variant variants viral evolution viral genome viral spike viral strain viral strains virus widespread zoonotic [DOI] 10.1371/journal.pone.0271359 PMC 바로가기 [Article Type] Article
Invariant in variants변이의 불변Article Published on 2022-08-012022-09-11 Journal: Ultrasonics [Category] 변종, [키워드] Biochemistry coronavirus demonstrated Effectiveness experiment flexible Frequency help IMPROVE mechanism mutate pandemic pathogen physical the vaccine ultrasound wave variant variants viral spike [DOI] 10.1016/j.ultras.2022.106749 PMC 바로가기 [Article Type] Article
Dual Inhibition of Vacuolar-ATPase and TMPRSS2 Is Required for Complete Blockade of SARS-CoV-2 Entry into CellsSARS-CoV-2 세포로의 진입을 완전히 차단하려면 Vacuolar-ATPase 및 TMPRSS2의 이중 억제가 필요합니다Article Published on 2022-07-192022-09-11 Journal: Antimicrobial Agents and Chemotherapy [Category] COVID19(2023년), SARS, 유전자 메커니즘, [키워드] absence Activation acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 ATPase bafilomycin block viral entry camostat cathepsin inhibitor Cathepsins Cell cellular Compound coronavirus E64d Efficacy endosomal pH endosomal protease endosome expressing highlight host cell host protease host proteases Hydroxychloroquine identify implicated Infection inhibit inhibiting inhibition inhibitor inhibitors Intervention life cycle Macrolide maturation mechanisms membrane fusion molecules Neutralizing nonspecific Pathways pharmacological agent Prevent protease Protein proteolytic activation provide pseudotyped rationale S protein SARS SARS-CoV-2 SARS-CoV-2 entry SARS-COV-2 infection Serine serine 2 serine proteases severe acute respiratory syndrome Coronavirus synergy the S protein these compound these compounds TMPRSS2 TMPRSS2 inhibitor TMPRSS2-expressing cells toxicities Toxicity transmembrane V-ATPase viral entry viral spike virus [DOI] 10.1128/aac.00439-22 PMC 바로가기 [Article Type] Article
A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate BindingSARS-CoV-2의 스파이크 수용체 결합 도메인과 친밀한 결합의 구조적 기초를 표적으로 하는 강력한 중화 나노바디Article Published on 2022-05-182022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 Basis binding binding affinity binding site biochemical analyses characterization competing complex coronavirus delta variant Diseases domain drug candidates engage epitope In-vitro increase nanobodies nanobody neutralization neutralization activity Neutralizing overlapping potent Potential treatment raised receptor related diseases respiratory reveal S-RBD SARS-CoV-2 SARS-CoV-2 S severe acute respiratory syndrome Coronavirus spike receptor-binding domain Spread structural basis target targeting the Spike These data Viral viral spike virus [DOI] 10.3389/fimmu.2022.820336 PMC 바로가기 [Article Type] Article
Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 bindingSARS-CoV-2 스파이크 당단백질-숙주 ACE2 결합을 강력하게 억제하는 남아프리카 공화국의 약용 식물인 Gunnera perpensa L.의 생리 활성 성분을 식별하기 위한 하이픈 연결 분석 기술의 사용Article Published on 2022-05-012022-09-11 Journal: Analytical and bioanalytical chemistry [Category] COVID19(2023년), SARS, 치료제, [키워드] ACE2 ACE2 binding African angiotensin Angiotensin-converting enzyme Antiviral antivirals binding causative agent cellular entry Compound Concentration COVID-19 described disrupt domain glycoprotein Gunnera Gunnera perpensa harmonization highlight Host hypothesised identify inhibit inhibit SARS-CoV-2 Interaction International Conference lack management morbidity and mortality neutralising antibody plant Protein Punicalagin Punicalin RBD RBD-ACE2 receptor Region REGN10987 SARS-CoV-2 SARS-COV-2 infection small molecule Small molecules South spike glycoprotein Spread UPLC UPLC-IMS-HRMS. Vaccines viral spike [DOI] 10.1007/s00216-022-04041-3 PMC 바로가기 [Article Type] Article
Berbamine hydrochloride potently inhibits SARS-CoV-2 infection by blocking S protein-mediated membrane fusionBerbamine 염산염은 S 단백질 매개 막 융합을 차단하여 SARS-CoV-2 감염을 강력하게 억제합니다Article Published on 2022-04-252022-09-11 Journal: PLoS Neglected Tropical Diseases [Category] COVID19(2023년), SARS, 치료제, [키워드] Antiviral antiviral activity antiviral agent Antiviral compounds antiviral drug antiviral drugs approved berbamine caused cell lines Clinical treatment COVID-19 drug effort experiment global pandemic global public health host cells Infection inhibit inhibit SARS-CoV-2 membrane fusion molecular docking outbreak Protein S-mediated cell-cell fusion SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 S2 severity subunit tested viral entry viral spike virus entry [DOI] 10.1371/journal.pntd.0010363 PMC 바로가기 [Article Type] Article
Structural conservation among variants of the SARS-CoV-2 spike postfusion bundleSARS-CoV-2 스파이크 후 융합 번들의 변종 간의 구조적 보존Article Published on 2022-04-192022-09-11 Journal: Proceedings of the National Academy of Sciences of [Category] COVID19(2023년), SARS, 변종, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Alter antiviral inhibitor antiviral inhibitors assembly change coronavirus COVID-19 COVID-19 vaccine COVID-19 vaccines cryo-EM cryogenic electron microscopy determine domain eight functional glycoprotein heptad repeat host cell HR1HR2 Interaction local effect membrane fusion Microscopy molecular monoclonal antibody mutant Mutation mutations Nostoc omicron Omicron variant postfusion related viruses reported resulting SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants selected severe acute respiratory syndrome Coronavirus similar studies similar study spike glycoprotein Structure structures target the SARS-CoV-2 therapy trimeric variant variants of SARS-CoV-2 Viral RNA viral spike wild-type [DOI] 10.1073/pnas.2119467119 PMC 바로가기 [Article Type] Article
Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2인간 진입 수용체 DPP4 및 ACE2를 표적으로 하는 SARS-CoV-2 스파이크 당단백질에 대한 이중특이성 항체 설계Article Published on 2022-04-012022-09-11 Journal: Human immunology [Category] COVID19(2023년), SARS, 바이오마커, 진단, [키워드] ACE2 Anti-viral antibody binding affinity Bispecific Antibody (BsAb) block China cleavage condition COVID-19 CrossMAb D614G disease DPP4 entry receptor epithelial cells Fc region global pandemic glycoprotein hACE2 hACE2 receptor heavy chain Host in-silico Infection KIH light chain linker lung alveolar lung alveolar epithelial cells modifications Molecular docking study mutated peptide performed Prevent receptor receptor engagement receptors regdanvimab Research SARS-CoV-2 SARS-CoV-2 spike glycoprotein spike spike glycoprotein Spike protein therapeutic target therapy Viral viral entry viral spike viral spike protein virus Wuhan [DOI] 10.1016/j.humimm.2022.01.004 PMC 바로가기 [Article Type] Article
Initial Experience With SARS-CoV-2-Neutralizing Monoclonal Antibodies in Kidney or Combined Kidney-Pancreas Transplant Recipients신장에서 SARS-CoV-2-중화 단일클론항체 또는 신장-췌장 결합 이식 환자에 대한 초기 경험Article Published on 2022-03-312022-09-11 Journal: Transplant International [Category] MERS, SARS, 변종, 진단, [키워드] Administered analyzed antibodies antiviral drugs appear bamlanivimab clinical outcomes co-primary endpoint co-primary endpoints Combined Contact coronavirus COVID-19 death drug effective Emergency use authorization EUA experience Hospitalization Hospitalized hospitalized patient identify Imdevimab Immunocompromised Immunosuppression IQR kidney Kidney transplantation lymphoma mAb median interval monoclonal antibodies monoclonal antibody Mortality negativity Organ transplant overall mortality Patient PCR negativity positive receive recipient recipients renal function respiratory Respiratory Coronavirus SARS-CoV-2 SARS-CoV-2 RT-PCR shown single dose single doses Spike protein Transplant treated Treatment U.S. FDA variant Viral viral spike viral spike protein virus-specific antibodies [DOI] 10.3389/ti.2022.10109 PMC 바로가기 [Article Type] Article